Roquefort Therapeutics plc (ROQAF)
OTC PINK OTC PINK Primary 
Roquefort Therapeutics sells Lyramid for $10.8mln - ICYMI
Roquefort Therapeutics PLC CEO Ajan Reginald talked with Proactive's Stephen Gunnion about the binding share purchase agreement with Pleiades Pharma for its wholly-owned subsidiary, Lyramid. The $10.8 million deal includes both shares and cash.
Roquefort Therapeutics shares up 19% on deal news
Shares in Roquefort Therapeutics PLC (LSE:ROQ, OTCQB:ROQAF) surged 19% in morning trade following the announcement of a term sheet to sell its subsidiary, Lyramid, to Pleiades Pharma for at least $10 million. The deal includes equity in Pleiades, which focuses on clinical and pre-clinical medicines and could involve upfront cash payments.
Roquefort Therapeutics signs term sheet for sale of Midkine portfolio for at least $10m
Roquefort Therapeutics PLC (LSE:ROQ, OTCQB:ROQAF) has signed a term sheet to sell its subsidiary, Lyramid, to Pleiades Pharma for at least $10 million. The deal includes equity in Pleiades and may involve upfront cash payments.
Roquefort presentation reveals the biotech is a leader in emerging targeted treatment field
Roquefort Therapeutics PLC (LSE:ROQ, OTCQB:ROQAF) will present new findings from its STAT-6 siRNA programme at the Advanced Therapy Development Congress in London later on Wednesday. The biopharmaceutical company focuses on pioneering treatments for immunology and oncology, aiming to disrupt disease processes at the genetic level.
Roquefort Therapeutics reports interest in its siRNA programmes
On the back of signing its first out-licensing deal, Roquefort Therapeutics PLC (LSE:ROQ, OTCQB:ROQAF) said it is also "engaging with multiple big pharma partners" interested in its siRNA programmes in immunology and inflammation. Also known as gene silencing, siRNA, or small interfering RNA, and is a field of research that has attracted a lot of attention industrywide with some big deals inked for early-stage assets.
Roquefort Therapeutics secures Japanese patent protection for MK technology; has big plans for the land of the rising sun
Roquefort Therapeutics PLC (LSE:ROQ, OTCQB:ROQAF) has secured a patent in Japan for its Mesodermal Killer (MK) cell therapy, a breakthrough in cancer and immune system treatments. This follows a similar intellectual property protection in Europe earlier this month.
Roquefort Therapeutics hails siRNA success in inflammation and immunology
Roquefort Therapeutics PLC (LSE:ROQ, OTCQB:ROQAF) notified investors that its STAT-6 siRNA has shown to work in an in-vitro experimental model of immunological disease, following direct feedback from potential big pharma partners. Medicines using siRNA technology are based on disrupting a gene's messaging machinery, with the London-listed biotech's programs targeting the STAT-6 proteins that selectively control how the key IL-4 and IL-13 proteins, which have a key role in inflammatory diseases.
Roquefort Therapeutics receives European patent grant
Roquefort Therapeutics PLC (LSE:ROQ, OTCQB:ROQAF) has passed a significant milestone with the European Patent Office, which granted a patent for its Mesodermal Killer (MK) cell therapy. This intellectual property protection covers 39 countries, including the UK and the EU, and solidifies the company's position in the rapidly growing field of cell-based immunotherapy.
Roquefort Therapeutics shares surge 24% on licensing deal term sheet news
Shares in Roquefort Therapeutics PLC (LSE:ROQ, OTCQB:ROQAF) rose 24% following the signing of a term sheet to out-license its Midkine antibody portfolio to Dubai-based PDC. The deal includes an upfront payment of $10 million.
Roquefort Therapeutics shares surge 24% on licensing deal term sheet news
Shares in Roquefort Therapeutics PLC (LSE:ROQ, OTCQB:ROQAF) rose 24% following the signing of a term sheet to out-license its Midkine antibody portfolio to Dubai-based PDC. The deal includes an upfront payment of $10 million.
Roquefort Therapeutics signs out-licensing term sheet potentially worth an initial $10m
Roquefort Therapeutics PLC (LSE:ROQ, OTCQB:ROQAF) said it has signed a term sheet to out-licence its Midkine antibody portfolio to Dubai-based contract research group PDC, which would include an upfront sum of $10 million. The immuno-oncology group also expects to receive a non-dilutive equity stake in a special purpose vehicle (SPV) that PDC will use to develop the Midkine antibodies.
Roquefort Therapeutics signs out-licensing term sheet potentially worth an initial $10m
Roquefort Therapeutics PLC (LSE:ROQ, OTCQB:ROQAF) said it has signed a term sheet to out-licence its Midkine antibody portfolio to Dubai-based contract research group PDC, which would include an upfront sum of $10 million. The immuno-oncology group also expects to receive a non-dilutive equity stake in a special purpose vehicle (SPV) that PDC will use to develop the Midkine antibodies.
